Pharmaceutical composition for treating inflammatory diseases comprising polypeptide derived from mycobacterium tuberculosis
A Mycobacterium tuberculosis-derived polypeptide specifically binding to NLRP3 inhibits the inflammasome activation, addressing the limitations of current treatments for inflammatory diseases by reducing inflammatory responses and tissue damage.
Patent Information
- Application Number
- PCT/KR2024/003334
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-08-10
- Filing Date
- 2024-03-18
- Publication Date
- 2024-12-05
AI Technical Summary
Current treatments for inflammatory diseases, such as Alzheimer's, atherosclerosis, and rheumatoid arthritis, are inadequate in effectively targeting the NLRP3 inflammasome, which plays a crucial role in chronic inflammatory responses and tissue damage.
A pharmaceutical composition containing a polypeptide derived from Mycobacterium tuberculosis, specifically binding to the NLRP3 protein, inhibits the activation of the NLRP3 inflammasome, thereby reducing inflammatory responses in various diseases.
The polypeptide effectively binds to NLRP3, reducing the activation of the inflammasome and subsequent secretion of pro-inflammatory cytokines, providing a potential treatment for a range of inflammatory diseases by modulating immune responses and reducing tissue damage.
Smart Images

Figure KR2024003334_05122024_PF_FP_ABST
Abstract
Description
Pharmaceutical composition for treating inflammatory diseases comprising a polypeptide derived from Mycobacterium tuberculosis
[0001] The present invention relates to a polypeptide derived from Mycobacterium tuberculosis that specifically binds to NLRP3, and a pharmaceutical composition for treating inflammatory diseases comprising the same.
[0002]
[0003] There are four known inflammasomes: NLRP1, NLRP3, NLRP4, and Aim2 inflammasomes, all of which contain PRRs belonging to the NLR family. Among these inflammasomes, the NLRP3 inflammasome plays a pivotal role in shaping immune responses and regulating the integrity of intestinal homeostasis in many common inflammatory diseases. NLRP3, a multiprotein complex composed of the NLRP3 scaffold, the adaptor apoptosis speck-like protein (ASC), and the effector procaspase-1, initiates the formation of the inflammasome by interacting with ASC. ASC recruits and activates procaspase-1, generating active caspase-1 and converting the cytokine precursors pro-IL-1β and pro-IL-18 into mature, biologically active IL-1β and IL-18, respectively. Once activated, active IL-1β and IL-18 induce a series of inflammatory responses and pyogenic cell death.
[0004] The NLRP3 inflammasome is produced by bone marrow-derived macrophages upon stimulation by microbial and non-microbial factors, such as bacterial toxins, particulate matter, and lipopolysaccharide (LPS). Although the mechanism of NLRP3 activation is not yet clearly understood, K + Leak, Ca 2+Several molecular and cellular events have been proposed to explain inflammasome activation, including signaling, mitochondrial dysfunction, and reactive oxygen species (ROS) production. For example, particulate matter induces endocytosis and damage to the lysosomal membrane, activating the NLRP3 inflammasome and releasing cathepsin B into the cytosol.
[0005]
[0006] The present invention aims to provide a polypeptide capable of treating inflammatory diseases by activating NLRP3 inflammasome.
[0007]
[0008] The present invention provides a polypeptide or a variant thereof comprising a sequence represented by SEQ ID NO: 1, which specifically binds to NLRP3 (NOD-, LRR-, and pyrin domain-containing protein 3) protein. In one embodiment of the present invention, the polypeptide consists of the sequence represented by SEQ ID NO: 1, and in another embodiment of the present invention, the polypeptide comprises the sequence represented by SEQ ID NO: 2, and in yet another embodiment of the present invention, the variant comprises a conservative substitution at a position excluding the 4th, 6th, and 7th amino acids of SEQ ID NO: 1, and in yet another embodiment of the present invention, the conservative substitution is at least one selected from the group consisting of F1Y, Y2F, A3G, F5Y, A8G, L9V, and S10T, or at least one selected from the group consisting of F1Y, Y2F, A3G, F5Y, A8G, L9I, and S10T.
[0009] The present invention provides an NLRP3-specific binding molecule comprising the above polypeptide or a variant thereof.
[0010] The present invention provides a pharmaceutical composition for treating an inflammatory disease, comprising the polypeptide or variant, and in one embodiment of the present invention, the inflammatory disease is Alzheimer's disease, atherosclerosis, asthma and allergic airway inflammation, gout, inflammatory bowel disease, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, myocardial infarction, multiple sclerosis or experimental autoimmune encephalitis, nephropathy, post-influenza hyperinflammation, graft-versus-host disease, stroke, silicosis, type 1 diabetes, obesity-induced inflammation or insulin resistance, rheumatoid arthritis, contact hypersensitivity, or traumatic brain injury.
[0011] The present invention provides a nucleic acid molecule expressing the above polypeptide or variant.
[0012] The present invention provides a pharmaceutical composition for treating an inflammatory disease, comprising the nucleic acid molecule, and in one embodiment of the present invention, the inflammatory disease is Alzheimer's disease, atherosclerosis, asthma and allergic airway inflammation, gout, inflammatory bowel disease, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, myocardial infarction, multiple sclerosis or experimental autoimmune encephalitis, nephropathy, post-influenza hyperinflammation, graft-versus-host disease, stroke, silicosis, type 1 diabetes, obesity-induced inflammation or insulin resistance, rheumatoid arthritis, contact hypersensitivity, or traumatic brain injury.
[0013] The present invention provides a recombinant vector comprising the above nucleic acid molecule.
[0014] The present invention provides a host cell comprising the nucleic acid molecule described above.
[0015]
[0016] The polypeptide of the present invention inhibits the activation of the NLRP3 inflammasome by specifically binding to the NLRP3 protein. Therefore, the polypeptide of the present invention, or a variant thereof, or a nucleic acid molecule expressing the same, can be used as a therapeutic agent for inflammatory diseases.
[0017]
[0018] Figure 1A shows the results of confirming the binding of NLRP3 and Rv0747 / PE_PGRS10, Figure 1B shows the results of confirming the binding site with Rv0747 / PE_PGRS10 through a deletion mutant of NLRP3, Figure 1C shows the results of confirming the binding activity of NLRP3 according to the position of Rv0747 / PE_PGRS10, and Figure 1D is a peptide sequence predicted as a site showing binding ability to NLRP3 in Rv0747 / PE_PGRS10.
[0019] FIG. 2A is a result confirming the degree of binding of NLRP3 and ASC according to peptide treatment according to one embodiment of the present invention, FIGS. 2B and 2C are results confirming the specific secretion inhibition ability for IL-1β, IL-18, and caspase-1 according to peptide treatment according to one embodiment of the present invention, and FIG. 2D is a result confirming that the peptide according to one embodiment of the present invention has superior binding ability to NLRP3 compared to ASC.
[0020] Figure 3 shows the results of confirming changes in ubiquitination (Figure 3A) and phosphorylation (Figure 3B) of the NRR domain by peptide treatment according to one embodiment of the present invention.
[0021] Figure 4 is a result of confirming the amino acid positions essential for binding to NLRP3 among peptides according to one embodiment of the present invention.
[0022]
[0023] Hereinafter, the present invention will be described in detail with reference to the attached drawings and embodiments thereof. However, the following embodiments are provided as examples of the present invention. If a detailed description of a technology or configuration well known to those skilled in the art is judged to unnecessarily obscure the gist of the present invention, such detailed description may be omitted, and the present invention is not limited thereby. The present invention is capable of various modifications and applications within the scope of the following claims and equivalents interpreted therefrom.
[0024] Additionally, the terminology used in this specification is intended to appropriately express preferred embodiments of the present invention, and may vary depending on the intent of the user or operator, or the customs of the field to which the present invention pertains. Therefore, the definitions of these terms should be determined based on the contents throughout this specification. Throughout this specification, when a part is said to "include" a certain component, unless specifically stated otherwise, this does not mean that other components are excluded, but rather that other components may be included.
[0025] Unless otherwise defined, all technical terms used in this invention have the same meaning as commonly understood by those skilled in the art. While preferred methods and samples are described herein, similar or equivalent methods are also included within the scope of the present invention. The contents of all publications cited herein as references are incorporated herein by reference.
[0026]
[0027] The NLRP3 inflammasome is a multiprotein complex that plays a central role in regulating the innate immune system and inflammatory signaling. Upon activation by pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), NLRP3 oligomerizes and activates caspase-1, which initiates the processing and release of the proinflammatory cytokines IL-1β and IL-18.
[0028] Diseases caused by activation of the NLRP3 inflammasome are readily observed in patients with gain-of-function mutations in NLRP3. Patients with these inherited autosomal dominant mutations in NLRP3 develop a systemic autoinflammatory syndrome called cryopyrin-associated periodic syndromes (CAPS). NLRP3, a pleiotropic antagonistic gene, is known to provide an advantage in controlling infections early in life, and given the plethora of damage-related stimuli sensed by NLRP3, it is thought to have evolved to initiate immune responses to tissue damage. Whatever evolutionary advantage NLRP3 may have in detecting and combating infections, it now contributes to many non-communicable diseases in the elderly population. The etiology of many common diseases in old age is influenced by chronic inflammation driven by the presence or accumulation of sterile danger signals in tissues. NLRP3 is the primary sensor for these types of sterile inflammatory signals and, therefore, a key driver of chronic inflammatory tissue responses in various diseases. NLRP3 has been implicated in a diverse range of diseases, and based on a combination of animal model studies and clinical data, it plays a key role in inflammatory diseases in four broad categories: metabolic dysfunction, diseases resulting from crystal or aggregate formation, acute tissue damage, or fibrosis secondary to chronic inflammation.
[0029] 최근까지 연구된 NLRP3의 활성화에 의해 발병되는 염증성 질환은 아래와 같다: 알츠하이머병 (Daniels, M. J. D. et al. Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models. Nat. Commun. 7, 1-10 (2016). This is the first paper to demonstrate that the fenamate class of NSAIDs, already approved by the FDA for other treatments, is able to inhibit NLRP3.;Heneka, M. T. et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP / PS1 mice. Nature 493, 674-678 (2014).;Dempsey, C. et al. Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-beta and cognitive function in APP / PS1 mice. Brain Behav. Immun. 61, 306-316 (2017).), 죽상경화증 (Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357-1361 (2010).;van der Heijden, T. et al. NLRP3 inflammasome inhibition by MCC950 reduces atherosclerotic lesion development in apolipoprotein E-deficient mice-brief report.Arterioscler. Thromb. Vasc. Biol. 37, 1457-1461 (2017).), 천식 및 알레르기성 기도 염증 (Besnard, A.-G. et al. NLRP3 inflammasome is required in murine asthma in the absence of aluminum adjuvant. Allergy 66, 1047-1057 (2011).;Kim, R. Y. et al. Role for NLRP3 inflammasome-mediated, IL-1beta-dependent responses in severe, steroid-resistant asthma. Am. J. Respir. Crit. Care Med. 196, 283-297 (2017).;Primiano, M. J. et al. Efficacy and pharmacology of the NLRP3 inflammasome inhibitor CP-456,773 (CRID3) in murine models of dermal and pulmonary inflammation. J. Immunol. 197, 2421-2433 (2016).), 통풍 (Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-241 (2006). This is the first report of a crystal that activates the NLRP3 inflammasome.;Goldberg, E. L. et al. b-Hydroxybutyrate deactivates neutrophil NLRP3 inflammasome to relieve gout flares. Cell Rep. 18, 2077-2087 (2017).;Ruiz-Miyazawa, K. W. et al.Quercetin inhibits gout arthritis in mice: induction of an opioid-dependent regulation of inflammasome. Inflammopharmacology https: / doi.org / 10.1007 / s10787-017-0356-x (2017).), 염증성 장 질환 및 관련 모델 (Liu, W. et al. A novel benzo[d]imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome. Biochem. Pharmacol. 85, 1504-1512 (2013).;Cocco, M. et al. Development of an acrylate derivative targeting the NLRP3 inflammasome for the treatment of inflammatory bowel disease. J. Med. Chem. 60, 3656-3671 (2017).;Bauer, C. et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 59, 1192-1199 (2010).;Neudecker, V. et al. Myeloid-derived miR-223 regulates intestinal inflammation via repression of the NLRP3 inflammasome. J. Exp. Med. 214, 1737-1752 (2017).), 비알코올성 지방간 질환 및 비알코올성 지방간염 (Henao-Mejia, J. et al.Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482, 179-185 (2012).;Wree, A. et al. NLRP3 inflammasome activation is required for fibrosis development in NAFLD. J. Mol. Med. 92, 1069-1082 (2014).;Mridha, A. R. et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J. Hepatol. 66, 1037-1046 (2017).), 심근 경색증 (Marchetti, C. et al. A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse. J. Cardiovasc. Pharmacol. 63, 316-322 (2014).;van Hout, G. P. J. et al. The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction. Eur. Heart J. 38, 828-836 (2017).;Sandanger, O. et al. The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury. Cardiovasc. Res. 99, 164-174 (2013).), 다발성 경화증 또는 실험적 자가면역 뇌염 (Coll, R. C.et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 21, 248-255 (2015). This is the first paper to demonstrate that CP-456,773 is a comprehensive, specific NLRP3 inhibitor.;Guo, C. et al. Development and characterization of a hydroxyl-sulfonamide analogue, 5-chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a novel NLRP3 inflammasome inhibitor for potential treatment of multiple sclerosis. ACS Chem. Neurosci. 8, 2194-2201 (2017).;Gris, D. et al. NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. J. Immunol. 185, 974-981 (2010).;Inoue, M. et al. Interferon-βtherapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome. Sci. Signal. 5, ra38 (2012).), 신병증 (Mulay, S. R. et al. Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1βsecretion. J. Clin. Invest.123, 236-246 (2012).;Ludwig-Portugall, I. et al. An NLRP3-specific inflammasome inhibitor attenuates crystal-induced kidney fibrosis in mice. Kidney Int. 90, 525-539 (2016).), 인플루엔자 감염 후 과염증 (Coates, B. M. et al. Inhibition of the NOD-like receptor protein 3 inflammasome is protective in juvenile influenza A virus infection. Front. Immunol. 8, 1-12 (2017).;Tate, M. D. et al. Reassessing the role of the NLRP3 inflammasome during pathogenic influenza A virus infection via temporal inhibition. Sci. Rep. 6, 27912 (2016).), 이식편대숙주병 (Jankovic, D. et al. The Nlrp3 inflammasome regulates acute graft-versus-host disease. J. Exp. Med. 210, 1899-1910 (2013).), 뇌졸중 (Ito, M. et al. Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury. Nat. Commun. 6, 1-11 (2015).;Yang, F. et al. NLRP3 deficiency ameliorates neurovascular damage in experimental ischemic stroke. J. Cereb. Blood Flow Metab. 34, 660-667 (2014).;Ren, H. et al.Selective NLRP3 (pyrin domain-containing protein 3) inflammasome inhibitor reduces brain injury after intracerebral hemorrhage. Stroke 49, 184-192 (2018).), 규폐증 (Cassel, S. L. et al. The Nalp3 inflammasome is essential for the development of silicosis. Proc. Natl Acad. Sci. USA 105, 9035-9040 (2008).), 제1형 당뇨병 (Hu, C. et al. NLRP3 deficiency protects from type 1 diabetes through the regulation of chemotaxis into the pancreatic islets. Proc. Natl Acad. Sci. USA 112, 11318-11323 (2015).), 비만 유발 염증 또는 인슐린 저항성 (Vandanmagsar, B. et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17, 179-188 (2011).;Jiang, H. et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J. Exp. Med. 214, 3219-3238 (2017).), 류머티스성 관절염 (Vande Walle, L. et al. Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis. Nature 512, 69-73 (2014).), 접촉 과민증 (Sutterwala, F. S. et al.Critical role for NALP3 / CIAS1 / Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 24, 317-327 (2006).;Primiano, M. J. et al. Efficacy and pharmacology of the NLRP3 inflammasome inhibitor CP-456,773 (CRID3) in murine models of dermal and pulmonary inflammation. J. Immunol. 197, 2421-2433 (2016).), 외상성 뇌 손상 (Irrera, N. et al. Lack of the Nlrp3 inflammasome improves mice recovery following traumatic brain injury. Front. Pharmacol. 8, 459 (2017).;Ismael, S., Nasoohi, S. & Ishrat, T. MCC950, the selective NLRP3 inflammasome inhibitor protects mice against traumatic brain injury. J. Neurotrauma 35, 1294-1303 (2018).).
[0030] The present invention provides a peptide derived from Mycobacterium tuberculosis that specifically binds to NLRP3 (NOD-, LRR-, and pyrin domain-containing protein 3) and can be used as a therapeutic agent for inflammatory diseases by inhibiting the activation of the NLRP3 inflammasome. More specifically, the peptide according to the present invention is derived from Rv0747 / PE_PGRS10 (SEQ ID NO: 2) of Mycobacterium tuberculosis. Wild-type Rv0747 / PE_PGRS10 consists of 801 amino acids. The present invention provides a peptide having the FYAQFVQALS sequence (SEQ ID NO: 1), which consists of the 72nd to 81st amino acids of Rv0747 / PE_PGRS10, that specifically binds to NLRP3. The DNA sequence encoding the full-length Rv0747 / PE_PGRS10 is represented by SEQ ID NO: 4, and the DNA sequence encoding SEQ ID NO: 1 is represented by SEQ ID NO: 3.
[0031] In relation to an amino acid sequence (peptide or protein), "fragment" means a part of the amino acid sequence, i.e. a sequence representing an amino acid sequence that is shortened at the N-terminus and / or C-terminus. A fragment shortened at the C-terminus (N-terminal fragment) can be obtained, for example, by translating a truncated open reading frame that lacks the 3'-end of the open reading frame. A fragment shortened at the N-terminus (C-terminal fragment) can be obtained, for example, by translating a truncated open reading frame that lacks the 5'-end of the open reading frame, as long as the truncated open reading frame includes an initiation codon that serves to initiate translation. A fragment of an amino acid sequence comprises, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% of the amino acid residues from the amino acid sequence. The fragment of the amino acid sequence preferably comprises at least 6, in particular at least 8, at least 12, at least 13, at least 14, at least 15, at least 20, at least 30, at least 50 or at least 100 consecutive amino acids from the amino acid sequence.
[0032] A "variant," "variant," "variant protein," or "variant polypeptide" of a polypeptide or protein refers to any analog, fragment, derivative, or mutant derived from the polypeptide or protein and retaining at least one biological property of the polypeptide or protein. Different variants of the polypeptide or protein may exist in nature. These variants may be allelic mutations characterized by differences in the nucleotide sequence of the structural gene encoding the protein, or may include differential splicing or post-translational modifications. One skilled in the art can generate variants having one or more amino acid substitutions, deletions, additions, or replacements. These variants may include, among others: (a) variants in which one or more amino acid residues are substituted with conservative or non-conservative amino acids, (b) variants in which one or more amino acids are added to the polypeptide or protein, (c) variants in which one or more of the amino acids comprises a substituent, and (d) variants in which the polypeptide or protein is fused to another polypeptide, such as serum albumin.
[0033] Conservative variants also refer to amino acid sequences with sequence changes that do not adversely affect the biological function of the protein. A substitution, insertion, or deletion is described as having an adverse effect on the protein if the altered sequence disrupts or destroys the biological function associated with the protein. For example, the overall charge, structure, or hydrophobic-hydrophilic properties of a protein can be altered without adversely affecting its biological activity. Thus, for example, an amino acid sequence can be altered to render a peptide more hydrophobic or more hydrophilic without adversely affecting the protein's biological activity. Techniques for obtaining such variants, including genetic (suppression, deletion, mutation, etc.), chemical, and enzymatic techniques, are known to those skilled in the art.
[0034] As used herein, "parent polypeptide," "parent protein," "precursor polypeptide," or "precursor protein" refers to an unmodified polypeptide that is later modified to form a variant. The parent polypeptide may be a wild-type polypeptide, or a variant or engineered version of a wild-type polypeptide.
[0035] As used herein, "wild type" or "WT" or "native" refers to an amino acid sequence found in nature, including allelic variants. A wild type protein or polypeptide has an amino acid sequence that has not been intentionally modified.
[0036] For the purposes of this specification, a "variant" of an amino acid sequence (peptide, protein or polypeptide) includes amino acid insertion variants, amino acid addition variants, amino acid deletion variants and / or amino acid substitution variants. The term "variant" includes all splice variants, post-translationally modified variants, conformations, isoforms and species homologs, particularly those naturally expressed by a cell. The term "variant" particularly includes fragments of an amino acid sequence.
[0037] Amino acid insertion variants comprise the insertion of one or more amino acids into a specific amino acid sequence. For amino acid sequence variants with insertions, one or more amino acid residues are inserted at specific sites in the amino acid sequence, although random insertions using appropriate screening of the resulting products are also possible. Amino acid addition variants comprise amino- and / or carboxy-terminal fusions of one or more amino acids, such as 1, 2, 3, 5, 10, 20, 30, 50, or more amino acids. Amino acid deletion variants are characterized by the deletion of one or more amino acids from the sequence, such as the deletion of 1, 2, 3, 5, 10, 20, 30, 50, or more amino acids. The deletions can be at any position in the protein. Amino acid deletion variants containing deletions at the N-terminus and / or C-terminus of a protein are also referred to as N-terminal and / or C-terminal truncation variants. Amino acid substitution variants are characterized by the deletion of one or more residues in the sequence and the insertion of another residue in its place. Preference is given to variants located in amino acid sequences that are not conserved between homologous proteins or peptides and / or to substitution of amino acids with other amino acids having similar properties.
[0038] In particular, the polypeptide according to the present invention may include conservative substitutions at positions other than the 2nd, 7th, 10th, and 13th amino acids of SEQ ID NO: 1. For example, a variant encompassed by the present invention is a protein comprising an amino acid sequence having 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence represented by SEQ ID NO: 1 or 2, which maintains functional identity with a protein consisting of the amino acid sequence represented by SEQ ID NO: 1 or 2.
[0039] Preferably, amino acid changes in peptide and protein variants are conservative amino acid changes, i.e., substitutions of similarly charged or uncharged amino acids. A conservative amino acid change involves substitution of one of the families of amino acids with similar side chains. Naturally occurring amino acids are generally divided into four families: acidic (aspartate, glutamate), basic (lysine, arginine, histidine), non-polar amino acids (alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), and non-charged polar amino acids (glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine). Phenylalanine, tryptophan, and tyrosine are sometimes classified together as aromatic amino acids. In one embodiment, a conservative amino acid substitution includes a substitution within the following groups:
[0040] Glycine, Alanine;
[0041] valine, isoleucine, leucine;
[0042] Aspartate, glutamate;
[0043] Asparagine, glutamine;
[0044] Serine, threonine;
[0045] Lysine, arginine; and
[0046] Phenylalanine, tyrosine.
[0047] In one embodiment of the present invention, a variant is provided that includes conservative substitutions, wherein phenylalanine at position 1 in SEQ ID NO: 1 is replaced with tyrosine (F1Y); tyrosine at position 2 is replaced with phenylalanine (Y2F); alanine at position 3 is replaced with glycine (A3G); phenylalanine at position 5 is replaced with tyrosine (F5Y); alanine at position 8 is replaced with glycine (A8G); leucine at position 9 is replaced with valine (L9V) or isoleucine (L9I); and / or serine at position 10 is replaced with threonine (S10T).
[0048]
[0049] The term “acidic amino acid residue” preferably relates to glutamic acid (glutamate, Glu) or aspartic acid (aspartate, Asp), particularly glutamic acid. The term “basic amino acid residue” relates to lysine (Lys) or arginine (Arg), particularly lysine.
[0050] Preferably, the degree of similarity, preferably identity, between a given amino acid sequence and an amino acid sequence that is a variant of said given amino acid sequence will be at least about 60%, 65%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. The degree of similarity or identity is preferably provided for an amino acid region that is at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% of the full length of the reference amino acid sequence. For example, if the reference amino acid sequence consists of 200 amino acids, the degree of similarity or identity is preferably provided for at least about 20, at least about 40, at least about 60, at least about 80, at least about 100, at least about 120, at least about 140, at least about 160, at least about 180 or about 200 amino acids, preferably contiguous amino acids. In a preferred embodiment, the degree of similarity or identity is provided for the full length of the reference amino acid sequence. Alignment for determining sequence similarity, preferably sequence identity, can be performed using tools known in the art, preferably using a best sequence alignment, such as Align, under standard settings, preferably EMBOSS::needle, Matrix: Blosum62, Gap Open 10.0, Gap Extend 0.5.
[0051] "Sequence similarity" refers to the percentage of amino acids that are identical or represent conservative amino acid substitutions. "Sequence identity" between two amino acid sequences refers to the percentage of amino acids that are identical between the sequences.
[0052] The term "% identity" is intended to refer to the percentage of identical amino acid residues between two sequences being compared, obtained by optimal alignment; this percentage is purely statistical, as the differences between the two sequences are distributed randomly and over their entire length. Sequence comparisons between two amino acid sequences are typically performed by optimally aligning them and then comparing them, with segments or "comparison windows" being used to identify and compare local regions of sequence similarity. Optimal alignment of sequences for comparison can be performed manually or by means of the local homology algorithm of Smith and Waterman, 1981, Ads App. Math. 2, 482, or by means of the local homology algorithm of Neddleman and Wunsch, 1970, J. Mol. Biol. 48, 443, or by means of the local homology algorithm of Pearson and Lipman, 1988, Proc. Natl Acad. Sci. By means of the similarity search methods of USA 85, 2444, or by using computer programs that utilize these algorithms (GAP, BESTFIT, FASTA, BLAST P, BLAST N, and TFASTA of the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Drive, Madison, Wis.).
[0053] % Identity is calculated by determining the number of identical positions between the two sequences being compared, dividing this number by the number of positions compared, and then multiplying the result by 100.
[0054] Homologous amino acid sequences according to the present disclosure exhibit at least 40%, particularly at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, and preferably at least 95%, at least 98% or at least 99% identity with respect to amino acid residues.
[0055] The amino acid sequence variants described herein can be readily prepared by those skilled in the art, for example, by recombinant DNA manipulation. Manipulation of DNA sequences to produce peptides or proteins with substitutions, additions, insertions, or deletions is described in detail, for example, in Sambrook et al. (1989). Furthermore, the peptides and amino acid variants described herein can be readily prepared using known peptide synthesis techniques, such as solid-phase synthesis and similar methods.
[0056] In one embodiment, the fragment or variant of an amino acid sequence (peptide or protein) is preferably a "functional fragment" or "functional variant." The term "functional fragment" or "functional variant" of an amino acid sequence relates to any fragment or variant that exhibits one or more functional properties identical or similar to the amino acid sequence from which it is derived, i.e., is a functional equivalent.
[0057] The term “functional fragment” or “functional variant,” as used herein, refers to a variant molecule or sequence that comprises an amino acid sequence in which one or more amino acids have been altered, particularly compared to the amino acid sequence of a parent molecule or sequence, and which is still capable of performing one or more functions of the parent molecule or sequence, e.g., binding to a target molecule or contributing to binding to a target molecule. In one embodiment, the alteration in the amino acid sequence of the parent molecule or sequence does not significantly affect or alter the binding characteristics of the molecule or sequence. In other embodiments, the binding of the functional fragment or functional variant may be reduced but still significantly present, e.g., the binding of the functional variant may be at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of that of the parent molecule or sequence. However, in other embodiments, the binding of the functional fragment or functional variant may be increased compared to the parent molecule or sequence.
[0058]
[0059] An amino acid sequence (peptide, protein or polypeptide) "derived from" a designated amino acid sequence (peptide, protein or polypeptide) means the origin of the first amino acid sequence. Preferably, an amino acid sequence derived from a particular amino acid sequence has an amino acid sequence that is identical, essentially identical or homologous to that particular sequence or a fragment thereof. An amino acid sequence derived from a particular amino acid sequence may be a variant of that particular sequence or a fragment thereof. For example, a person skilled in the art will appreciate that Rv0747 / PE_PGRS10 suitable for use herein may be modified in sequence from a naturally occurring or native sequence derived therefrom, but which retains the desired activity of the native sequence.
[0060] "Isolated" means altered or removed from its natural state. For example, a nucleic acid or peptide naturally occurring in a living animal is not "isolated," but the same nucleic acid or peptide partially or completely separated from its natural coexisting materials is "isolated." An isolated nucleic acid or protein may exist in a substantially purified form, or it may exist in a non-natural environment, such as a host cell.
[0061]
[0062] In the context of the present invention, the term "recombinant" means "created through genetic manipulation." Preferably, a "recombinant subject," such as a recombinant cell, in the context of the present invention does not occur naturally.
[0063] As used herein, the term “naturally occurring” means that a subject can be found in nature. For example, a peptide or nucleic acid is naturally occurring if it exists within an organism (including a virus), can be isolated from a source in nature, and has not been intentionally modified by humans in a laboratory.
[0064] The term "genetic modification" encompasses transfecting a cell with a nucleic acid. The term "transfection" relates to the introduction of a nucleic acid, particularly RNA, into a cell. For all purposes of the present invention, the term "transfection" also encompasses the introduction of a nucleic acid into a cell or the uptake of a nucleic acid by such a cell. For some applications of transfection, it is sufficient if the transfected genetic material is only transiently expressed. RNA can be transfected into a cell and cause it to transiently express its encoded protein. Because the nucleic acid introduced during transfection is generally not integrated into the nuclear genome, the foreign nucleic acid will be diluted or degraded through mitosis. Cells capable of episomal amplification of nucleic acid significantly reduce the dilution rate. If the transfected nucleic acid is to persist in the cell and its progenitor cells, stable transfection must occur. Such stable transfection can be achieved using a virus-based or transposon-based transfection system. Typically, cells that are genetically modified to express a receptor polypeptide and / or an antigen receptor are stably transfected with a nucleic acid encoding the receptor polypeptide and / or a nucleic acid encoding the antigen receptor, whereas typically, a nucleic acid encoding a ligand polypeptide and / or a nucleic acid encoding an antigen are transiently transfected into the cell.
[0065] The terms "nucleic acid", "nucleic acid molecule", "oligonucleotide" and "polynucleotide" are used interchangeably and refer to a polymer of the phosphate esters of ribonucleosides (adenosine, guanosine, uridine or cytidine; "RNA molecule") or deoxyribonucleosides (deoxyadenosine, deoxyguanosine, deoxythymine or deoxycytidine; "DNA molecule"), either in single-stranded or double-stranded helix form, or any of their phosphate ester analogs such as phosphorothioates and thioesters. Double-stranded DNA-DNA, DNA-RNA and RNA-RNA helices are possible. The term nucleic acid molecule, and in particular DNA or RNA molecule, refers only to the primary and secondary structures of said molecules and is not limited to any particular tertiary configuration. Accordingly, the term encompasses, among others, linear or circular DNA molecules (e.g., restriction fragments), plasmids, supercoiled DNA, and double-stranded DNA found in chromosomes. When discussing the structure of a particular double-stranded DNA molecule, the sequence may be described herein according to the general convention of presenting the sequence only in the 5' to 3' direction along the non-transcribed DNA strand (i.e., the strand having the sequence matching the mRNA). A "recombinant DNA molecule" is a DNA molecule that has undergone molecular biological manipulation. DNA includes, but is not limited to, cDNA, genomic DNA, plasmid DNA, synthetic DNA, and semi-synthetic DNA.
[0066] The nucleic acid may be contained within a vector. The term “vector,” as used herein, includes any vector known to those skilled in the art, including plasmid vectors, cosmid vectors, phage vectors such as lambda phage, viral vectors such as retrovirus, adenovirus, or baculovirus vectors, or artificial chromosome vectors such as bacterial artificial chromosomes (BAC), yeast artificial chromosomes (YAC), or P1 artificial chromosomes (PAC). Such vectors include expression as well as cloning vectors. Expression vectors include plasmids as well as viral vectors, and generally contain the desired coding sequence and appropriate DNA sequences necessary for the expression of the coding sequence operably linked thereto in a particular host organism (e.g., bacteria, yeast, plants, insects, or mammals) or in vitro expression system. Cloning vectors are generally used to manipulate and amplify a particular desired DNA fragment and may lack functional sequences necessary for the expression of the desired DNA fragment.
[0067] Viral vectors have been used for a wide range of gene transfer applications in living animals as well as cells. Viral vectors that may be used include, but are not limited to, adenovirus, retrovirus, vaccinia virus, poxvirus, adeno-associated virus, herpes simplex virus, lentivirus, baculovirus, sendai virus, measles virus, simian virus 40, and Epstein-Barr virus vectors. Non-viral vectors include plasmids, lipoplexes (cationic liposome-DNA complexes), polyplexes (cationic polymer-DNA complexes), and protein-DNA complexes. In addition to the nucleic acid, the vector may include one or more regulatory regions and / or selectable markers that are useful for selecting, measuring, and monitoring the outcome of the nucleic acid delivery (e.g., delivery to tissues, persistence of expression, etc.).
[0068] The term "expression vector" refers to a vector, plasmid, or vehicle designed to transform a host cell after expressing an inserted nucleic acid sequence. The cloned gene, i.e., the inserted nucleic acid sequence, is typically placed under the control of regulatory elements such as a promoter, a minimal promoter, an enhancer, and the like. Numerous initiation regulatory regions or promoters useful for directing expression of nucleic acids in a desired host cell are well known to those skilled in the art. Virtually any promoter capable of directing expression of these genes includes, but is not limited to, viral promoters, bacterial promoters, animal promoters, mammalian promoters, synthetic promoters, constitutive promoters, tissue-specific promoters, pathogenesis- or disease-related promoters, developmental-specific promoters, inducible promoters, and lightly regulated promoters;SV40 early (SV40) promoter region, promoter contained in the 3' long terminal repeat (LTR) of Rous sarcoma virus (RSV), E1A or major late promoter (MLP) of adenovirus (Ad), human cytomegalovirus (HCMV) immediate early promoter, herpes simplex virus (HSV) thymidine kinase (TK) promoter, baculovirus IE1 promoter, elongation factor 1 alpha (EF1) promoter, glyceraldehyde-3-phosphate dehydrogenase (GSPDH) promoter, phosphoglycerate kinase (PGK) promoter, ubiquitin C (Ubc) promoter, albumin promoter, mouse metallothionein-L Regulatory sequences of promoters and transcriptional regulatory regions, ubiquitous promoters (HPRT, vimentin, β-actin, tubulin, etc.), intermediate filaments (desmin, neurofilament, keratin, GFAP, etc.), promoters of therapeutic genes (MDR, CFTR, or factor VIII form, etc.), pathogenesis- or disease-related promoters, and promoters that exhibit tissue specificity and have been used in transgenic animals, such as the elastase I gene regulatory region active in pancreatic acinar cells; the insulin gene regulatory region active in pancreatic beta cells, the immunoglobulin gene regulatory region active in lymphoid cells, the mouse mammary carcinoma virus regulatory region active in testicular, breast, lymphoid, and macrophage cells;Including, but not limited to, the albumin gene active in the liver, Apo AI and Apo AII regulatory regions, the alpha-fetoprotein gene regulatory region active in the liver, the alpha1-antitrypsin gene regulatory region active in the liver, the beta-globin gene regulatory region active in bone marrow cells, the myelin basic protein regulatory region active in oligodendrocyte cells in the brain, the myosin light chain-2 gene regulatory region active in skeletal muscle, and the gonadotropic releasing hormone, pyruvate kinase promoter, villin promoter, fatty acid-binding intestinal protein promoter, and smooth muscle cell β-actin promoter active in the hypothalamus;
[0069] Vectors can be transfected by methods known in the art, such as injection, transfection, electroporation, microinjection, transduction, cell fusion, lipofection, calcium phosphate precipitation (Graham, FL et al., Virology, 52:456(1973); and Chen and Okayama, Mol. Cell. Biol. 7:2745-2752(1987)), liposome-mediated transfection (Wong, TK et al., Gene, 10:87(1980); Nicolau and Sene, Biochim. Biophys. Acta, 721:185-190(1982); and Nicolau et al., Methods Enzymol., 149:157-176(1987)), DEAE-dextran treatment (Gopal, Mol. Cell Biol., 5:1188-1190 (1985)), gene bombardment (Yang et al., Proc. Natl. Acad. Sci., 87:9568-9572 (1990)), use of a gene gun, or DNA vector transporters (e.g., Wu et al., J. Biol. Chem. 267:963 (1992); Wu et al., J. Biol. Chem. 263:14621 (1988); and Hartmut et al., Canadian Patent Application No. 2,012,311, see).
[0070] Polynucleotides according to the present invention can be introduced in vivo by lipofection. Over the past several decades, the use of liposomes for in vitro nucleic acid encapsulation and transfection has increased. Synthetic cationic lipids, designed to limit the difficulties and risks encountered with liposome-mediated transfection, can be used to prepare liposomes for in vivo gene transfection (Felgner et al., Proc. Natl. Acad. Sci. USA. 84:7413 (1987); Mackey et al., Proc. Natl. Acad. Sci. USA 85:8027 (1988); and Ulmer et al., Science 259:1745 (1993)). The use of cationic lipids can facilitate the encapsulation of negatively charged nucleic acids and also promote fusion with negatively charged cell membranes (Felgner et al., Science 337:387 (1989)). Particularly useful lipid compounds and compositions for nucleic acid delivery are described in WO95 / 18863, WO96 / 17823, and US 5,459,127. The use of lipofection to introduce exogenous genes into specific tissues in vivo offers several practical advantages. Molecular targeting of liposomes to specific cells offers one area of advantage. Direct transfection into specific cell types would clearly be particularly desirable in tissues with cellular heterogeneity, such as the pancreas, liver, kidney, and brain. Lipids can be chemically linked to other molecules for targeting purposes (Mackey et al. 1988). Targeted peptides, such as hormones or neurotransmitters, and proteins, such as antibodies, or non-peptide molecules can be chemically bound to liposomes.
[0071] Other molecules, such as cationic oligopeptides (e.g., WO95 / 21931), peptides derived from DNA binding proteins (e.g., WO96 / 25508), or cationic polymers (e.g., WO95 / 21931), are also useful for facilitating transfection of nucleic acids in vivo.
[0072] It is also possible to introduce vectors in vivo as naked DNA plasmids (see U.S. Patent Nos. 5,693,622, 5,589,466, and 5,580,859). Receptor-mediated DNA transfer may also be used (Curiel et al., Hum. Gene Ther. 3:147 (1992); and Wu et al., J. Biol. Chem. 262:4429 (1987)).
[0073] The nucleic acids described herein may be recombinant and / or isolated molecules.
[0074] In the context of this specification, the term "transcription" refers to the process by which the genetic code in a DNA sequence is transcribed into RNA. The RNA can then be translated into peptides or proteins.
[0075] “Encoding” refers to the inherent property of a specific sequence of nucleotides in a polynucleotide, such as a gene, cDNA, or mRNA, to serve as a template for the synthesis of other polymers and macromolecules in biological processes, having a defined sequence of nucleotides (i.e., rRNA, tRNA, and mRNA) or a defined sequence of amino acids and the biological properties derived therefrom. Thus, a gene encodes a protein if the transcription and translation of the mRNA corresponding to that gene produces a protein in a cell or other biological system. Both the coding strand, which is identical to the mRNA sequence and is usually provided as a sequence listing, and the non-coding strand, which serves as a template for transcription of the gene or cDNA, may be said to encode a protein or other product of that gene or cDNA.
[0076] The present invention provides a host cell comprising the vector of the present invention. The host cell includes prokaryotic (e.g., bacterial) and eukaryotic (e.g., fungal, yeast, animal, insect, plant) cells and may be any cell suitable for expressing a polypeptide according to the present invention. Suitable prokaryotic host cells include, but are not limited to, Escherichia coli (e.g., strains DH5, HB101, JM109, or W3110), Bacillus, Streptomyces, Salmonella, Serratia, and Pseudomonas species. Suitable eukaryotic host cells include, but are not limited to, COS, CHO, HepG-2, CV-1, LLCMK2, 3T3, HeLa, RPMI8226, 293, BHK-21, Sf9, Saccharomyces, Pichia, Hansenula, Kluyveromyces, Aspergillus or Trichoderma species.
[0077] As used herein, “endogenous” means any substance derived from or produced within an organism, cell, tissue, or system.
[0078] As used herein, “exogenous” means any substance derived from or produced outside an organism, cell, tissue, or system.
[0079] As used herein, the term “expression” refers to the biological production of a product encoded by a coding sequence, and can be defined as the transcription and / or translation of a specific nucleotide sequence. In most cases, a DNA sequence comprising a coding sequence is transcribed to form messenger RNA (mRNA). This messenger RNA is then translated to form a polypeptide product having the relevant biological activity. The expression process may also include additional processing steps for the RNA transcript product (e.g., splicing to remove introns) and / or post-translational processing of the polypeptide product.
[0080] As used herein, the terms "linked," "fused," or "fusion" are used interchangeably. These terms mean that two or more elements, components, or domains are joined together.
[0081]
[0082] The peptides, proteins, polypeptides, RNAs, RNA particles and additional agents, e.g., immune checkpoint inhibitors, described herein can be administered as pharmaceutical compositions or medicaments for therapeutic or prophylactic treatment, and can be administered in the form of any suitable pharmaceutical composition, which can include a pharmaceutically acceptable carrier and optionally can include one or more adjuvants, stabilizers, etc. In one embodiment, the pharmaceutical composition is for use in therapeutic or prophylactic treatment, e.g., treating or preventing an inflammatory disease, such as those described herein.
[0083]
[0084] The term "pharmaceutical composition" relates to a formulation comprising a therapeutically effective substance, preferably together with a pharmaceutically acceptable carrier, diluent, and / or excipient. The pharmaceutical composition is useful for reducing the severity of, preventing, or treating a disease or disorder by administering the pharmaceutical composition to a subject. Pharmaceutical compositions are also known in the art as pharmaceutical dosage forms. In the context of the present invention, a pharmaceutical composition comprises a peptide, protein, polypeptide, RNA, RNA particle, immune effector cell, and / or additional substance as described herein.
[0085]
[0086] The pharmaceutical compositions of the present disclosure may include one or more adjuvants or may be administered together with one or more adjuvants. The term "adjuvant" refers to a compound that prolongs, enhances, or accelerates an immune response. Adjuvants include heterogeneous compounds such as oil emulsions (e.g., Freund's adjuvant), mineral compounds (e.g., alum), bacterial products (e.g., pertussis toxin), or immune-stimulating complexes. Examples of adjuvants include, but are not limited to, LPS, GP96, CpG oligodeoxynucleotides, growth factors, and cytokines such as monokines, lymphokines, interleukins, and chemokines. Cytokines may be IL1, IL2, IL3, IL4, IL5, IL6, IL7, IL8, IL9, IL10, IL12, IFNα, IFNγ, GM-CSF, or LT-a. Additionally known adjuvants are aluminum hydroxide, Freund's adjuvant or oils such as Montanide®ISA51.
[0087] Pharmaceutical compositions according to the present specification are generally applied as “pharmaceutically effective amounts” and “pharmaceutically acceptable formulations.”
[0088] The term "pharmaceutically acceptable" means the non-toxicity of a substance that does not interact with the action of the active ingredient of the pharmaceutical composition.
[0089] The term "pharmaceutically effective amount" or "therapeutically effective amount" means an amount that, alone or in combination with additional administration, achieves the desired response or effect. In the treatment of a specific disease, the desired response preferably means inhibition of the progression of the disease. This includes slowing the progression of the disease, and particularly includes stopping or reversing the progression of the disease. In the treatment of a disease, the desired response may also be delaying the onset or preventing the onset of the disease or condition. The effective amount of the compositions described herein will be determined based on the individual characteristics of the patient, including the condition being treated, the severity of the disease, age, physical condition, height, and weight, the duration of treatment, the type of concomitant therapy (if any), the specific route of administration, and similar factors. Accordingly, the dosage of the compositions described herein can be determined based on these various characteristics. If the patient does not respond sufficiently with the first dose, a higher dose (or a higher dose achieved effectively by another, more localized route of administration) may be used.
[0090] The pharmaceutical compositions of the present disclosure may include salts, buffers, preservatives, and optionally other therapeutic agents. In one embodiment, the pharmaceutical compositions of the present disclosure include one or more pharmaceutically acceptable carriers, diluents, and / or excipients.
[0091]
[0092] Preservatives suitable for use in the pharmaceutical compositions of the present disclosure include, but are not limited to, benzalkonium chloride, chlorobutanol, parabens and thimerosal.
[0093] As used herein, the term "excipient" refers to a substance that may be present in a pharmaceutical composition of the present disclosure but is not an active ingredient. Examples of excipients include, but are not limited to, carriers, binders, diluents, lubricants, thickeners, surfactants, preservatives, stabilizers, emulsifiers, buffers, flavoring agents, or coloring agents.
[0094] The term "diluent" refers to a substance that dilutes and / or thins. Furthermore, the term "diluent" encompasses any one or more of a fluid, liquid, or solid suspension, and / or mixed medium. Examples of suitable diluents include ethanol, glycerol, and water.
[0095] The term "carrier" refers to a component which may be natural, synthetic, organic, or inorganic that is combined with an active ingredient to facilitate, enhance, or enable administration of the pharmaceutical composition. As used herein, a carrier may be one or more compatible solid or liquid fillers, diluents, or encapsulating materials suitable for administration to a subject. Suitable carriers include, but are not limited to, sterile water, Ringer's, Ringer's lactate, sterile sodium chloride solution, isotonic saline, polyalkylene glycols, hydrogenated naphthalenes, and, in particular, biocompatible lactide polymers, lactide / glycolide copolymers, or polyoxyethylene / polyoxy-propylene copolymers. In one embodiment, the pharmaceutical compositions herein comprise isotonic saline.
[0096] Pharmaceutically acceptable carriers, excipients or diluents for therapeutic use are well known in the art of pharmacy and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R Gennaro edited. 1985).
[0097] Pharmaceutical carriers, excipients or diluents may be selected depending on the intended route of administration and standard pharmaceutical practice.
[0098] In one embodiment, the pharmaceutical compositions described herein can be administered intravenously, intraarterially, subcutaneously, intradermally, or intramuscularly. In certain embodiments, the pharmaceutical compositions are formulated for topical or systemic administration. Systemic administration can include enteral administration involving absorption through the gastrointestinal tract or parenteral administration. As used herein, "parenteral administration" means administration by any means other than through the gastrointestinal tract, such as intravenous injection. In a preferred embodiment, the pharmaceutical compositions are formulated for systemic administration. In another preferred embodiment, systemic administration is by intravenous administration. In one embodiment of all aspects of the invention, the polypeptides described herein, or variants thereof, or nucleic acid molecules encoding them, are administered systemically.
[0099] As used herein, the term "co-administration" refers to the administration of multiple compounds or compositions (e.g., immune effector cells, a polypeptide described herein or a variant thereof or nucleic acid molecule encoding the same, and optionally an RNA encoding a vaccine antigen) to the same patient. The multiple compounds or compositions may be administered simultaneously, essentially simultaneously, or sequentially.
[0100] The materials, compositions, and methods described herein can be used to treat individuals with diseases, such as diseases characterized by the presence of disease-causing cells expressing antigens. Particularly preferred diseases are inflammatory diseases.
[0101] The term "disease" refers to an abnormal condition affecting an individual's body. A disease is often interpreted as a medical condition associated with specific symptoms and signs. A disease may be caused by an agent originating from an external source, such as an infectious disease, or by an internal dysfunction, such as an autoimmune disease. In humans, "disease" is used in a broader sense to refer to any condition that, upon contact with the individual, causes pain, dysfunction, distress, social problems, death, or similar problems to the affected individual. In a broader sense, it sometimes includes injuries, disabilities, disorders, syndromes, infections, isolated symptoms, deviant behaviors, and structural and functional atypical alterations, which, in different contexts and for different purposes, can be considered distinct categories. Disease typically affects individuals not only physically but also emotionally, as living with various diseases can alter an individual's outlook on life and personality.
[0102] As used herein, the terms "treat," "treating," and "treatment," and "prevent," "preventing," and "prevention" mean inducing a desired biological response, such as a therapeutic and preventive effect, respectively. In some embodiments, the therapeutic effect comprises one or more of: reducing / reducing the inflammatory disease, reducing / reducing the severity of the inflammatory disease (e.g., reducing or inhibiting the development of the inflammatory disease), reducing / reducing symptoms and inflammatory disease-related effects, delaying the onset of symptoms and inflammatory disease-related effects, reducing the symptom severity of inflammatory disease-related effects, reducing the severity of acute episodes, reducing symptoms and inflammatory disease-related effects, reducing the latency of symptoms and inflammatory disease-related effects, improving symptoms and inflammatory disease-related effects, reducing secondary symptoms, reducing secondary infections, preventing relapses to the inflammatory disease, or reducing the frequency of relapse episodes, increasing the latency between symptom episodes, increasing the time to sustained progression, promoting remission, inducing remission, increasing remission, accelerating recovery, or increasing the efficacy of or decreasing resistance to alternative therapies, and / or increasing the survival time of a subject following administration of the agent or a composition comprising the agent. Prophylactic effects may include complete or partial avoidance / inhibition or delay of the development / progression of an inflammatory disease (e.g., complete or partial avoidance / inhibition or delay), and increased survival time of a subject following administration of the treatment protocol. Treatment of an inflammatory disease includes treating a subject already diagnosed with any form of an inflammatory disease at any clinical stage or manifestation, delaying the onset or development or worsening or worsening of symptoms or signs of an inflammatory disease, and / or preventing and / or reducing the severity of an inflammatory disease.
[0103] The term "therapeutic treatment" means any treatment that improves the health status of a subject and / or prolongs (increases) the lifespan of a subject. Such treatment may result in the elimination of a disease in a subject, the arrest or slowing of the progression of a disease in a subject, the inhibition or slowing of the progression of a disease in a subject, the reduction in the frequency or severity of symptoms in a subject, and / or the reduction in recurrence in a subject currently suffering from or previously suffering from a disease.
[0104]
[0105] The term "prophylactic treatment" or "preventive treatment" refers to any treatment intended to prevent the development of a disease in a subject. The terms "prophylactic treatment" and "preventive treatment" are used interchangeably herein.
[0106]
[0107] The terms "individual" and "subject" are used interchangeably herein. These terms refer to a human or other mammal (e.g., a mouse, rat, rabbit, dog, cat, cow, pig, sheep, horse, or primate) that may be susceptible to or may be susceptible to a disease or disorder (e.g., an inflammatory disease), but may or may not have been afflicted with the disease or disorder. In many embodiments, the subject is a human. Unless otherwise specified, the terms "individual" and "subject" do not imply a particular age, and thus encompass adults, elderly people, children, and newborns. In embodiments herein, an "individual" or "individual" is a "patient."
[0108]
[0109] The term "patient" means an individual or entity in need of treatment, specifically an individual or entity suffering from a disease.
[0110]
[0111] As used herein, “immune response” refers to a coordinated body response to an antigen or cells expressing an antigen, and refers to a cellular immune response and / or a humoral immune response.
[0112] The terms “cell-mediated immunity”, “cellular immunity”, “cellular immune response”, or similar terms are meant to include cellular responses directed against cells characterized by the expression of antigens, particularly by presentation of antigens with class I or class II MHC molecules. The cellular response involves cells called T cells or T lymphocytes that function either as “helper” or “killer” cells. Helper T cells (also called CD4+ T cells) play a central role by regulating the immune response, while killer cells (cytotoxic T cells, cytolytic T cells, CD8 + T cells (also called CTLs or T cells) kill cells that have inflammatory diseases, preventing the development of more diseased cells.
[0113] This specification contemplates immune responses that may be protective, prophylactic, prophylactic, and / or therapeutic. As used herein, "inducing [or inducing] an immune response" may mean the absence of an immune response to a particular antigen prior to induction, or it may mean that an immune response to a particular antigen exists at a baseline level prior to induction and is enhanced following induction. Thus, "inducing [or inducing] an immune response" includes "enhancing [or enhancing] an immune response."
[0114] The term "immunotherapy" refers to the treatment of a disease or condition by inducing or enhancing an immune response. The term "immunotherapy" includes antigen immunization or antigen vaccination.
[0115] The term "immunization" or "vaccination" refers to the process of administering an antigen to an individual for the purpose of inducing an immune response, for example, for therapeutic or prophylactic reasons.
[0116] The term "macrophage" refers to a subset of phagocytes produced by the differentiation of monocytes. Activated by inflammation, immune cytokines, or microbial products, macrophages nonspecifically engulf and degrade exogenous pathogens within the macrophage by hydrolytic and oxidative attack. Peptides derived from the degraded proteins are presented on the cell surface of the macrophage, where they can be recognized by T cells and interact directly with antibodies on the surface of B cells, activating T and B cells and further stimulating the immune response. Macrophages belong to the class of antigen-presenting cells. In one embodiment, the macrophages are splenic macrophages.
[0117] The term "dendritic cell" (DC) refers to a subtype of phagocyte belonging to the antigen-presenting cell class. In one embodiment, dendritic cells are derived from hematopoietic bone marrow progenitor cells. These progenitor cells first transform into immature dendritic cells. These immature cells are characterized by high phagocytic activity and low T-cell activation potential. Immature dendritic cells continuously sample their surroundings for pathogens such as viruses and bacteria. Once they encounter a presentable antigen, they are activated into mature dendritic cells and begin migrating to the spleen or lymph nodes. Immature dendritic cells phagocytose pathogens, degrade their proteins into small fragments, and upon maturation, present these fragments on their surface using MHC molecules. Simultaneously, these cells upregulate cell-surface receptors, such as CD80, CD86, and CD40, which act as co-receptors in T-cell activation, significantly enhancing their T-cell activation capacity. They also upregulate CCR7, a chemotactic receptor that induces dendritic cells to migrate to the spleen via the bloodstream or to lymph nodes via the lymphatic system. Here, they act as antigen-presenting cells, activating B cells by antigen presentation, as well as helper T cells and killer T cells, in conjunction with non-antigen-specific co-stimulatory signals. Thus, dendritic cells can actively induce T- or B-cell-mediated immune responses. In one embodiment, the dendritic cells are splenic dendritic cells.
[0118] The term "antigen-presenting cell" (APC) refers to a variety of cells capable of displaying, acquiring, and / or presenting at least one antigen or antigen fragment on (or at) their surface. Antigen-presenting cells can be divided into professional antigen-presenting cells and non-professional antigen-presenting cells.
[0119] The term "professional antigen-presenting cell" refers to an antigen-presenting cell that constitutively expresses major histocompatibility complex class II (MHC class II) molecules required for interaction with naive T cells. When a T cell interacts with the MHC class II molecule complex on the antigen-presenting cell's membrane, the antigen-presenting cell produces co-stimulatory molecules that induce T cell activation. Professional antigen-presenting cells include dendritic cells and macrophages.
[0120] The term "non-professional antigen-presenting cell" refers to an antigen-presenting cell that does not constitutively express MHC class II molecules upon stimulation by specific cytokines, such as interferon-gamma. Examples of non-professional antigen-presenting cells include fibroblasts, thymic epithelial cells, thyroid epithelial cells, glial cells, pancreatic beta cells, or vascular endothelial cells.
[0121] "Antigen processing" means breaking down an antigen into processing products, which are fragments of said antigen (e.g., breaking down a protein into peptides) and combinations of one or more of these fragments with an MHC molecule (e.g., through binding) for presentation by a cell, such as an antigen presenting cell, to a specific T cell.
[0122] The term "disease involving an antigen" refers to any disease associated with an antigen, such as a disease characterized by the presence of an antigen. The disease involving an antigen may be an infectious disease or an inflammatory disease. As described above, the antigen may be a disease-associated antigen, such as a tumor-associated antigen, a viral antigen, or a bacterial antigen. In one embodiment, the disease involving an antigen is a disease involving cells that express the antigen, preferably on the surface of the cells.
[0123] The term "infectious disease" refers to any disease that can be transmitted from one individual to another or from organism to organism and is caused by a microbial agent (e.g., a cold). Infectious diseases are well known in the art and include, for example, viral, bacterial, or parasitic diseases caused by viruses, bacteria, and parasites, respectively. In this regard, infectious diseases can be, for example, hepatitis, sexually transmitted diseases (e.g., chlamydia or gonorrhea), tuberculosis, HIV / acquired immunodeficiency syndrome (AIDS), diphtheria, hepatitis B, hepatitis C, cholera, severe acute respiratory syndrome (SARS), avian influenza, and influenza.
[0124] In the present invention, “inflammatory disease” means a disease caused by inflammation in the body due to various causes, and in one embodiment of the present invention, the inflammatory disease is Alzheimer’s disease, atherosclerosis, asthma and allergic airway inflammation, gout, inflammatory bowel disease, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, myocardial infarction, multiple sclerosis or experimental autoimmune encephalitis, nephropathy, post-influenza hyperinflammation, graft-versus-host disease, stroke, silicosis, type 1 diabetes, obesity-induced inflammation or insulin resistance, rheumatoid arthritis, contact hypersensitivity, or traumatic brain injury.
[0125]
[0126] References to the literature and research cited herein are not intended to be an admission that any of the aforementioned content is related to the prior art. All references to the contents of these documents are based on information available to the applicant and do not constitute any admission as to the accuracy of the contents of these documents.
[0127]
[0128] The following description is provided to enable those skilled in the art to create and utilize various embodiments. Descriptions of specific devices, techniques, and applications are provided solely as examples. Various modifications to the embodiments described herein will readily become apparent to those skilled in the art, and the general principles defined herein may be applied to other embodiments and applications without departing from the spirit and scope of the various embodiments. Therefore, the various embodiments are not intended to be limited to the embodiments described and illustrated herein, but are intended to be consistent with the scope of the claims.
[0129]
[0130] Example
[0131] 1. Materials and Methods
[0132] 1.1 Mice and Tissue Culture
[0133] Wild-type C57BL / 6 mice were supplied by Samtako Bio Korea (Osan, Korea). Primary bone marrow-derived macrophages (BMDMs) were collected from the mice and cultured in DMEM with M-CSF (R&D Systems, 416-ML) for 3–5 days. HEK293T cells (ATCC-11268; American Type Culture Collection) were cultured in DMEM (Gibco) containing 10% fetal bovine serum (FBS) (Gibco), nonessential amino acids, sodium pyruvate, streptomycin (100 μg / mL), and penicillin (100 IU / mL).
[0134]
[0135] 1.2 Reagents and Antibodies
[0136] Lipopolysaccharide (LPS) (Escherichia coli O111:B4, tlrl-eblps), adenosine 5'-triphosphate (ATP, tlrl-atpl), nigericin, and dextran sulfate sodium (DSS) were purchased from Invivogen. Actin (I-19), ASC (N-15-R), IL-18 (H-173-Y), caspase-1 p10 (M-20), HA (12CA5), Flag (D-8), GST (B-14), His (H-3), and V5 (C-9) were purchased from Santa Cruz Biotechnology. IL-1β and NLRP3 (AG-20B-0014) were from R&D system and Adipogen, respectively.
[0137]
[0138] 1.3 Plasmid construction
[0139] GST-Rv0747, Flag-NLRP3, V5-ASC, and HA-Ub plasmids were purchased from Addgene. Wild-type NLRP3 (Int. J. Mol. Sci. 2020, 21, 8437) is 1036 amino acids long, and ΔPYD, ΔNACHT, 1-219 and 537-1036 in wtNLRP3, and ΔLRR, 1-741 in wtNLRP3 were used. Plasmids for expressing full-length (FL) NLRP3 and mutants (ΔPYD, ΔNACHT, and ΔLRR) were inserted into the pcDNA3 vector. Plasmids encoding different regions of Rv0747 (1-801, 1-93, 94-200, 201-300, 301-400, 401-500, 501-600, 601-700, 701-800) were amplified by PCR from FL Rv0747 cDNA and subcloned into pEBG derivatives encoding N-terminal GST epitope tags flanked by BamHI and NotI sites. Plasmids encoding different regions of ASC (1-195, 1-91, 107-195) were generated by PCR amplification from FL ASC cDNA and subcloned into pEF derivatives encoding C-terminal Flag tags between BamHI and NotI sites. All transient proteins encoded in the plasmids were produced in mammalian cells using the pEBG-GST mammalian fusion vector and the pEF-IRES-Puro expression vector. All constructs were sequenced using an ABI PRISM 377 automated DNA sequencer to ensure 100% identity with the original sequence.
[0140]
[0141] 1.4 Peptides
[0142] NLRP3 or ASC peptides conjugated with 9R were provided by Peptron (Daejeon, South Korea), manufactured and purified in acetate form to avoid undesirable intracellular reactions. Endotoxin levels were measured using the Limulus amebocyte lysate test (Charles River Endosafe ®Endochrome-K™USA), and the peptide concentrations used in the experiments were less than 3–5 pg / mL.
[0143]
[0144] 1.5 GST pulldown, immunoblot, and immunoprecipitation assays
[0145] GST pulldown, Western blot, and co-immunoprecipitation assays were performed with 293T and BMDM cells. For GST pulldown, 293T cells were harvested and lysed in NP40 buffer supplemented with a protease inhibitor cocktail (Roche, Basal, CH). After centrifugation, the supernatant was pretreated with protein A / G beads for 2 h at 4°C. The pretreated lysate was combined with a 50% slurry of glutathione-conjugated Sepharose beads (Amersham Biosciences, Amersham, UK) and incubated for 4 h at 4°C. The precipitate was thoroughly rinsed with lysis buffer. Proteins bound to the glutathione beads were eluted by boiling in sodium dodecyl sulfate (SDS) loading buffer for 5 min. For immunoprecipitation analysis, cells were harvested and lysed in NP40 buffer supplemented with a protease inhibitor cocktail (Roche, Basal, CH). Whole-cell lysates were pretreated with protein A / G agarose beads for 1 h at 4°C and then immunoprecipitated with the treated antibodies. Typically, 1 mL of cell lysate was treated with 1–4 μg of antibody for 8–12 h at 4°C. After 6 h of incubation with protein A / G agarose beads, immunoprecipitates were thoroughly washed with lysis buffer and eluted by boiling in SDS loading buffer for 5 min. Polypeptides were separated by SDS-polyacrylamide gel electrophoresis and transferred to PVDF membranes for immunoblotting (IB) (Bio-Rad, Hercules, CA, USA). Specific antibodies were required for immunodetection, and chemiluminescence (ECL; Millipore, MA, USA) was used to visualize the antibody bound to the target. A Vilber chemiluminescence analyzer (Fusion SL3; Vilber Lourmat, Colegien, France) was used for detection.
[0146]
[0147] 1.6 Enzyme-linked immunosorbent assay
[0148] TNF-α, IL-6, IL-1β, and IL-18 levels were measured in cell culture supernatants and mouse serum using the BD OptEIA ELISA system (BD Pharmingen). All assays were performed according to the manufacturer's instructions.
[0149]
[0150] 1.7 Kinetic analysis of NLRP3 interaction with ASC binding partners
[0151] Rv0747 72 FYAQFVQALS 81 - NLRP3 interactions were monitored using a Fluormax-4 spectrophotometer (HORIBA Scientific) as described previously. Rv0747 according to the manufacturer's instructions. 72 FYAQFVQALS 81 Or NLRP3 labeled BODIPY FL Iodoacetamide (ThermoFisher Scientific). Rv0747 72 FYAQFVQALS 81 Alternatively, the NLRP3 label was excited at 350 nm and detected through a cutoff filter at 512 nm. Rv0747 72 FYAQFVQALS 81 Alternatively, NLRP3 was designated as unlabeled NLRP3 or ASC for kinetic analysis. The excitation and emission wavelengths used were 498 nm and 518 nm, respectively. The acquired data were analyzed using the Grafit program, and all fluorescence measurements were performed at 25°C in 30 mM Tris, pH 7.4, 150 mM NaCl, and 1 mM dithiothryitol.
[0152]
[0153] 2. Results
[0154] 2.1 The LRR domain of NLRP3 and the PE domain of Rv0747 interact with each other.
[0155] The NLRP3 inflammasome complex plays a crucial role as a host cell defense mechanism against pathogens. To identify the antigenic protein of Mycobacterium tuberculosis that binds to this NLRP3 protein, recombinant NLRP3 (rNLRP3-His) was co-immunoprecipitated with Mycobacterium tuberculosis H37Rv lysate and purified using His-agarose beads. The purified rNLRP3-His complex was analyzed by silver staining and liquid chromatography-mass spectrometry, confirming that the NLRP3 protein binds to the Mycobacterium Rv0747 / PE_PGRS10 protein (Fig. 1A).
[0156] The NLRP3 protein is composed of PYD, NACHT, and LRR domains. To identify the domains through which NLRP3 and Rv0747 interact, GST-tagged Rv0747 (GST-Rv0747) and Flag-tagged NLRP3 WT, PYD-deficient NLRP3 (ΔNACHT), and LRR-deficient NLRP3 (ΔLRR) were transfected into 293T cells, and a GST pull-down assay was performed. When immunodetected with a Flag antibody, Flag-NLRP3 WT, ΔPYD, and ΔNACHT were detected, but Flag-NLRP3 ΔLRR was not (Fig. 1B).
[0157] The following Rv0747 / PE_PGRS10 is composed of PE and other domains, and the entire GST-Rv0747 domain (1-801), the PE domain (1-93), and domains divided into approximately 100 amino acids each, as well as Flag-NLRP3, were used. Only the entire domain and the PE domain of Rv0747 were detected (Fig. 1C), indicating that the PE domain interacts with the LRR domain of NLRP3. In addition, the protein sequence of the PE domain was analyzed using the PredictProtein tool, and it was confirmed that the 10 amino acid sequence from positions 72 to 81 is likely to be important for the interaction with the NLRP3 protein (Fig. 1D).
[0158]
[0159] 2.2 Rv0747-derived peptide inhibits NLRP3 inflammasome activation.
[0160] To confirm the role of the interaction between NLRP3 and Rv0747, an Rv0747-derived peptide (Rv0747) that interacts with NLRP3 in combination with the cell-penetrating peptide R9 (RRRRRRRRR) was used. 72 FYAQFVQALS 81 ) was produced. NLRP3 binds to the adapter protein ASC to form inflammasome. Therefore, Flag-NLRP3 and V5-ASC were transfected into 293T cells, and the binding between NLRP3 and ASC was observed after treatment with peptides in a concentration-dependent manner. As a result, the binding between NLRP3 and ASC was reduced in proportion to the concentration of Rv0747-derived peptide. In addition, when bone marrow-derived macrophages (BMDMs) were stimulated with LPS and ATP to activate NLRP3 inflammasome and treated with Rv0747-derived peptide, the binding between NLRP3 and ASC was confirmed to be reduced (Fig. 2A).
[0161] Once formed, inflammasomes secrete proinflammatory cytokines, interleukin (IL)-1β / 18. LPS-stimulated BMDMs were treated with NLRP3 inflammasome activators (ATP, Nigericin, DSS, MSU, Alum), AIM2 inflammasome activator (poly(dA:dT)), NLRC4 inflammasome activator (flagellin), and NLRP1b inflammasome activator (LTx) and Rv0747-derived peptides, and IL-1β / 18 was confirmed using enzyme-linked immunosorbent assay and immunoblotting. The Rv0747-derived peptide specifically reduced only IL-1β / 18 secretion induced by NLRP3 inflammasome activation, and immunoblot results also showed that it reduced only the secretion of IL-1β / 18 and caspase-1, an effector protein of the inflammasome, upon NLRP3 inflammasome activation (Fig. 2B and Fig. 2C).
[0162] In vitro interactions between NLRP3 and Rv0747-derived peptides or ASC were evaluated by fluorescent labeling experiments using NLRP3-derived peptides or ASC, which showed higher affinity between NLRP3 and Rv0747-derived peptides (Rv0747 72 FYAQFVQALS 81 , 296 nM; ASC, 432 nM) (Fig. 2D).
[0163] Taken together, these results indicate that the interaction of NLRP3 with the Rv0747-derived peptide reduces the binding of NLRP3 to ASC and specifically inhibits only NLRP3 inflammasome activation.
[0164]
[0165] 2.3 Rv0747-derived peptide regulates inflammasome activation through direct binding to NLRP3.
[0166] Mutations in the LRR domain of NLRP3 negatively regulate NLRP3 inflammasome activation. Therefore, we examined whether interaction with an Rv0747-derived peptide increases ubiquitination and phosphorylation of the LRR domain of NLRP3.
[0167] When Flag-NLRP3-LRR was ubiquitinated and treated with Rv0747-derived peptide in a concentration-dependent manner, ubiquitination of Flag-NLRP3-LRR did not change regardless of peptide concentration (Fig. 3A). Similarly, the tyrosine phosphorylation form of Flag-NLRP3-LRR did not change regardless of peptide concentration (Fig. 3B).
[0168] In conclusion, Rv0747-derived peptide inhibits NLRP3 inflammasome activation through direct binding rather than modification of the LRR domain of NLRP3.
[0169]
[0170] 2.4 Rv0747 72 FYAQFVQALS 81 The QXVQ amino acid affects binding to NLRP3.
[0171] Short linear motifs, such as peptides, can be functionally enhanced or lost by one or two point mutations. Rv0747 72 FYAQFVQALS 81 We also examined whether point mutations in certain amino acids could affect the interaction with NLRP3. Rv0747 72 FYAQFVQALS 81The QXVQ portion in the middle part of the amino acid sequence was symmetrical, so that position 75 Q was mutated to L, position 77 V to H, and position 78 Q to L, respectively. As a result, it was observed that Flag-NLRP3 and point-mutated GST-Rv0747 did not bind to each other (Fig. 4), indicating that each amino acid may play an important role in binding to NLRP3.
[0172]
[0173] For example, for purposes of claim construction, the claims set forth below should not be construed narrowly beyond their literal language, and thus, exemplary embodiments from the specification should not be construed as claims. Therefore, it should be understood that the present invention has been described by way of example only, and not as a limitation on the scope of the claims. Accordingly, the present invention is limited only by the claims below. All publications, issued patents, patent applications, books, and journal articles cited in this application are hereby incorporated by reference in their entirety.
[0174]
[0175] SEQ ID NO: 1
[0176] FYAQFVQALS
[0177]
[0178] SEQ ID NO: 2
[0179] MSWVMVSPEL VVAAAADLAG IGSAISSANA AAAVNTTGLL TAGADEVSTA IAALFGAQGQ APPLICATION AFYAQFVQAL SAGGGAYAAA EAAAVSPLLA PINAQFVAAT GRPLIGNGAN GAPGTGANGG PGGWLIGNGG AGGSGAPGAG AGGNGGAGGL FGSGGAGGAS TDVAGGAGGA GGAGGNAGML FGAAGVGGVG GFSNGGATGG AGGAGGAGGL FGAGRERGSG GSGNLTGGAG GAGGNAGTLA TGDGGAGGTG GASRSGGFGG AGGAGGDAGM FFGSGGSGGA GGISKSVGDS AAGGAGGAPG LIGNGGNGGN GGASTGGGDG GPGGAGGTGV LIGNGGNGGS GGTGATLGKA GIGGTGGVLL GLDGFTAPAS TSPLHTLQQD VINMVNDPFQ TLTGRPLIGN GANGTPGTGA DGGAGGWLFG NGGNGGQGTI GGVNGGAGGA GGAGGILFGT GGTGGSGGPG ATGLGGIGGA GGAALLFGSG GAGGSGGAGA VGGNGGAGGN AGALLGAAGA GGAGGAGAVG GNGGAGGNGG LFANGGAGGP GGFGSPAGAG GIGGAGGNGG LFGAGGTGGA GGGSTLAGGA GGAGGNGGLF GAGGTGGAGS HSTAAGVSGG AGGAGGDAGL LSLGASGGAG GSGGSSLTAA GVVGGIGGAG GLLFGSGGAG GSGGFSNSGN GGAGGAGGDA GLLVGSGGAG GAGASATGAA TGGDGGAGGK SGAFGLGGDG GAGGATGLSG AFHIGGKGGV GGSAVLIGNG GNGGNGGNSG NAGKSGGAPG PSGAGGAGGL LLGENGLNGL M
[0180]
[0181] SEQ ID NO: 3
[0182] ttttacgccc agttcgtgca ggccctgagc
[0183]
[0184] SEQ ID NO: 4
[0185] atgtcatggg tgatggtttc gccggagctg gtggtggcgg cggcagcgga tttggcgggg atcgggtcgg cgattagctc ggctaatgcg gcggcggccg tcaacacgac gggattgttg accgcgggtg ccgatgaggt gtcgacagcg attgcggcgt tgttcggtgc ccaaggccag gcctaccagg cggcgagcgc acaggcggcg gcgttttacg cccagttcgt gcaggccctg agcgccggcg gaggcgcgta tgcggccgcc gaggccgccg ccgtgtcgcc gctgctggcc ccgatcaacg cgcaattcgt ggcggccacc gggcgcccgc tgatcggcaa cggcgccaac ggcgcccccg ggaccggagc caacggcggg cccggcgggt ggttgatcgg caacggcggc gccggcgggt ctggcgcccc cggcgctggg gccggcggta acggcggggc cggcgggctg ttcggcagcg gcggggccgg cggggcctcc accgacgtcg ccggcggggc cggtggggcc ggcggggccg gcggaaacgc cggcatgctg ttcggcgccg ccggggtcgg cggcgtcggc ggattctcga acggcggtgc caccggcggg gcaggcgggg ccggcggggc gggcgggctg tttggcgccg gaagggaacg cggcagcggc gggtcgggca acctcactgg cggggccggc ggggccggcg gcaacgccgg gacactcgcc actggtgatg gcggggccgg cgggaccggc ggcgctagtc gcagcggcgg attcggcggg gccggcggag ccggcggcga cgccggcatg ttcttcggct ccggcggctc cggcggcgcc ggcggcatta gtaaaagcgt cggggacagc gccgccggcggggccggcgg ggcccccggg ctgatcggca acggcggcaa cggcggcaac ggcggcgcga gcaccggcgg cggggacggt gggcccggcg gggccggcgg caccggcgtg ttgatcggca acggcggcaa cggcggcagc ggcgggaccg gcgcgaccct gggcaaggcc ggcatcggcg gtaccggggg ggtgctgttg ggcctggacg gctttacggc ccccgccagc acctcgcccc tgcacaccct gcagcaggac gtgatcaata tggtgaacga ccccttccag acgctcaccg ggcgtccgct gatcggcaac ggcgccaacg gcactccggg gaccggggct gacggcggag ccggcggctg gttgttcggc aacggcggaa acggcgggca gggaacgatc ggcggcgtca acggcggggc cggcggggcc ggcggggccg gcgggatctt gttcggcacc ggcggcaccg ggggcagcgg cgggcccggc gccaccggcc tcggcgggat tggcggggcc ggcggagccg ccttgctctt cggctccggc ggggccggcg gaagcggtgg tgccggcgcg gtcggtggca atggcggggc cggcggcaac gccggtgcgc tcttgggcgc cgccggggcc ggcggggccg gtggtgccgg cgcggtcggt ggcaatggcg gggccggcgg taacggcggg ctgttcgcca acgggggagc cggcgggccc ggtgggtttg gcagccccgc tggggctggc gggatcggcg gggcaggtgg gaacggcggg ctgttcggcg ccggcgggac cggcggggcc ggcgggggaa gcaccctcgc cggcggcgcc ggcggggcgg gcggcaacgg cgggctgttc ggcgccggcg gcaccggcggcgccggcagc catagcaccg ccgccggagt ttccggaggg gccggcgggg ccggcggcga cgccggcttg ctctccctcg gcgcctccgg cggggccggc ggcagcggcg gttccagcct gaccgccgcc ggcgtggtcg gcggcatcgg cggcgccgga ggcttgctct tcggctccgg cggcgccggc gggagcggcg ggttcagcaa ctctggcaac ggcggcgccg gcggggccgg cggcgacgcg ggtttgctcg tcggctccgg cggggccggc ggggccggcg cctccgccac cggcgccgcc accggcgggg acggcggggc cggcggcaag tccggagcgt tcggtctcgg aggtgacggc ggcgccggcg gcgccaccgg tttgtccggt gctttccaca tcggcggcaa gggcggcgtc ggcggcagcg ccgtgctgat cggcaacggc ggcaacggcg gcaacggcgg taacagcggt aacgccggga aatccggggg tgcacccggc cccagcggcg ccggcggcgc cggcgggctg ctgctcggtg agaacgggct gaacggcttg atgtag
Claims
1. A polypeptide comprising a sequence represented by SEQ ID NO: 1 or a variant thereof, which specifically binds to NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) protein.
2. In the first paragraph, the polypeptide or a variant thereof is composed of a sequence represented by SEQ ID NO:
1.
3. In the first paragraph, the polypeptide or a variant thereof comprises a sequence represented by SEQ ID NO:
2.
4. A polypeptide or a variant thereof, in the first paragraph, wherein the variant comprises a conservative substitution at positions other than the 4th, 6th, and 7th amino acids of SEQ ID NO:
1.
5. A polypeptide or variant thereof, in claim 4, wherein the conservative substitution is at least one selected from the group consisting of F1Y, Y2F, A3G, F5Y, A8G, L9V, and S10T, or at least one selected from the group consisting of F1Y, Y2F, A3G, F5Y, A8G, L9I, and S10T.
6. An NLRP3-specific binding molecule comprising a polypeptide of any one of claims 1 to 5 or a variant thereof.
7. A pharmaceutical composition for treating an inflammatory disease, comprising a polypeptide or variant of any one of claims 1 to 5.
8. A pharmaceutical composition for treating an inflammatory disease according to claim 7, wherein the inflammatory disease is Alzheimer's disease, atherosclerosis, asthma and allergic airway inflammation, gout, inflammatory bowel disease, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, myocardial infarction, multiple sclerosis or experimental autoimmune encephalitis, nephropathy, post-influenza hyperinflammation, graft-versus-host disease, stroke, silicosis, type 1 diabetes, obesity-induced inflammation or insulin resistance, rheumatoid arthritis, contact hypersensitivity, or traumatic brain injury.
9. A nucleic acid molecule expressing a polypeptide or variant of any one of claims 1 to 5.
10. A pharmaceutical composition for treating an inflammatory disease, comprising the nucleic acid molecule of claim 9.
11. A pharmaceutical composition for treating an inflammatory disease according to claim 10, wherein the inflammatory disease is Alzheimer's disease, atherosclerosis, asthma and allergic airway inflammation, gout, inflammatory bowel disease, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, myocardial infarction, multiple sclerosis or experimental autoimmune encephalitis, nephropathy, post-influenza hyperinflammation, graft-versus-host disease, stroke, silicosis, type 1 diabetes, obesity-induced inflammation or insulin resistance, rheumatoid arthritis, contact hypersensitivity, or traumatic brain injury.
12. A recombinant vector comprising the nucleic acid molecule of paragraph 9.
13. A host cell comprising the nucleic acid molecule of claim 9.
14. A method for treating an inflammatory disease, comprising administering to a patient in need of treatment a polypeptide or variant of any one of claims 1 to 5.
15. A method for treating an inflammatory disease, comprising administering the nucleic acid molecule of claim 9 to a patient in need of treatment.
Citation Information
Patent Citations
A computer apparatus for identifying adhesin and adhesin-like proteins of therapeutic potential
KR101178776B1
Tumbler to aid in the storage and storage of solid pills
KR1020210099811A
Fenceless cooperative robot having safety function
KR1020230112814A
Modulators of the NLRP3 inflammasome il-1beta pathway for the prevention and treatment of acne
US20140199320A1
Methods of treating or selecting a treatment for a subject resistant to TNF inhibitor using a NLRP3 antagonist
WO2020010118A1
